Try our Advanced Search for more refined results
Life Sciences
- 
									September 23, 2025
									OTC Drug Co. Must Face Shampoo Cancer Risk Class ActionA Pennsylvania federal judge denied Lake Consumer Products Inc.'s request to toss a putative class action alleging it manufactures coal tar shampoo with known carcinogens, reasoning that most of the claims against the company were plausible enough to move forward. 
- 
									September 23, 2025
									CBP Says It Didn't Coordinate With Apple In Import Ban CaseU.S. Customs and Border Protection told a D.C. federal court Monday that contrary to claims by Masimo Corp., emails between the agency and Apple Inc. do not show the two worked together to evade an import ban on the Apple Watch in a patent dispute with Masimo. 
- 
									September 23, 2025
									Eli Lilly Deal In Weight Loss Drugs Trademark Suit Hits SnagPharmaceutical giant Eli Lilly and two Seattle-area medical clinics tried to leave a federal court "entirely in the dark" on the finer points of their newly proposed trademark suit settlement, a Seattle federal judge held in declining to approve the deal and enter a consent judgment in the case. 
- 
									September 23, 2025
									Google, Meta Beat BlueChew Users' Privacy Suit, For NowA California federal judge Tuesday dismissed a proposed class action alleging Google and Meta illegally gathered information from website users buying erectile dysfunction medication on BlueChew's website, since BlueChew's revised policy makes clear their personal data consisting of health information would be shared with third parties for advertising purposes. 
- 
									September 23, 2025
									Stem Cell Co. Beats Investor Suit Over Failed Janssen CollabBiopharmaceutical company Fate Therapeutics Inc. has shed a proposed investor class action alleging it concealed manufacturing challenges, precipitating the blowup of a potentially lucrative partnership, after a San Diego federal judge found its investors failed to show how their losses were caused by the company's alleged misstatements. 
- 
									September 23, 2025
									This Week In Healthcare CybersecurityExpiring Obama-era cybersecurity legislation, U.K. charges for 'Scattered Spider' breach, and the challenges of 23andMe's bankruptcy. Law360 looks at the week in cybersecurity developments affecting the healthcare industry. 
- 
									September 23, 2025
									Axsome Settles Investors' Drug Approval Suit For $7.8MBiopharmaceutical company Axsome Therapeutics Inc. and its shareholders have asked a New York federal court to approve a $7.75 million settlement to resolve investors' claims that Axsome hid issues related to gaining regulatory approval for its migraine drug. 
- 
									September 23, 2025
									Fed. Circ. Gives Bayer Chance To Save Xarelto Patent ClaimsThe Federal Circuit revived several claims of a patent underpinning Bayer Pharma Aktiengesellschaft's blockbuster blood thinner Xarelto on Tuesday, sending the challenge brought by Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc. and a Cipla unit back to the Patent Trial and Appeal Board. 
- 
									September 23, 2025
									Tylenol MDL In Spotlight After Trump Blasts Use In PregnancyThe Trump administration's attack on the use of acetaminophen during pregnancy drew on the work of a Harvard expert whose analysis is central to a legal clash now before a federal appeals court. The president's broadside promises to energize plaintiffs. 
- 
									September 23, 2025
									How Attys Are Riding The Mass. Biotech 'Roller Coaster'The first half of 2025 saw the Massachusetts biotech industry post bleak numbers, including a dip in venture capital funding and merger activity, leaving attorneys looking for creative ways to help companies with fewer public and private dollars. 
- 
									September 23, 2025
									NC Sens. Vote To Cut Planned Parenthood's Medicaid FundsRepublican state senators in North Carolina have greenlit a bill that would revoke Medicaid funding for Planned Parenthood, aligning the Tar Heel state with the president's "One Big Beautiful Bill," which prohibits Medicaid funding for nonprofit groups that provide abortion services. 
- 
									September 23, 2025
									Pfizer Settles Conn. Zantac Lawsuits Alleging Cancer RisksPfizer Inc. has settled two Connecticut state court lawsuits by patients who claimed generic forms of ranitidine, the heartburn and acid reflux drug sold under the brand name Zantac, degraded into a substance that caused cancer. 
- 
									September 23, 2025
									EX-CTA Worker's $425K Vaccine Bias Award Capped At $300KAn Illinois federal judge lowered a former Chicago Transit Authority employee's $425,000 jury award to $300,000 Tuesday for the ex-worker's claim that he was wrongly fired for refusing the COVID-19 vaccine, entering a judgment the judge said he'll later amend with awards that include back and front pay. 
- 
									September 23, 2025
									Two Longtime HHS Attys Depart Posts For Crowell & MoringTwo prominent U.S. Department of Health and Human Services attorneys have left their posts for Crowell & Moring LLP after more than two decades in the federal government. 
- 
									September 23, 2025
									Foley & Lardner Adds Healthcare Deals Pro From Holland & KnightFoley & Lardner LLP has continued its expansion in Nashville with the addition of another former Holland & Knight LLP attorney, expanding its healthcare and life sciences and manufacturing sector capabilities. 
- 
									September 23, 2025
									HealthTrackRx Names 2nd Chief Legal Officer In 2025Texas-based infectious disease laboratory HealthTrackRx has added a new chief legal officer following the departure of the top attorney it hired earlier this year. 
- 
									September 22, 2025
									5th Circ.'s 340B Ruling 'Limited,' Pharma Cos. Tell 4th Circ.The Fifth Circuit's recent refusal to block a Mississippi law regulating the delivery of discounted drugs to rural providers can't be wielded by West Virginia in its battle over the law's constitutionality because of the distinctions between the two state laws, a coalition of pharmaceutical companies told the Fourth Circuit. 
- 
									September 22, 2025
									In-House Judge Won't Pause FTC's Heart Valve Deal ChallengeAn administrative law judge refused to pause the Federal Trade Commission's in-house case challenging Edwards Lifesciences Corp.'s planned $945 million purchase of JenaValve Technology Inc. until after a ruling in the related federal court case. 
- 
									September 22, 2025
									J&J Ruling Misapplied Goldman Precedent, 3rd Circ. ToldThe U.S. Chamber of Commerce and other business organizations are supporting Johnson & Johnson's call for the full Third Circuit to reconsider a ruling that the groups argue could "saddle" companies with investor class-action suits through the misapplication of a recent U.S. Supreme Court ruling. 
- 
									September 22, 2025
									Catching Up With Delaware's Chancery CourtLast week, Match.com secured approval for a $30M settlement over its 2019 reverse spinoff from IAC, and Vice Chancellor Morgan T. Zurn urged decorum among Delaware lawyers, comparing recent legal turmoil to dark times in British monarchy history. Here's the latest from the Chancery Court. 
- 
									September 22, 2025
									CVS's Omnicare Hits Ch. 11 After $949M FCA JudgmentOmnicare LLC, CVS Health's subsidiary that provides pharmacy services for long-term care facilities, filed for Chapter 11 bankruptcy relief Monday in Texas following a $949 million judgment against Omnicare and CVS issued by a New York federal judge earlier this year. 
- 
									September 22, 2025
									Wachtell, Paul Weiss Advise On Pfizer's $7.3B Obesity PathPfizer Inc. will acquire Metsera Inc. for $4.9 billion in cash, as the U.S. pharmaceutical giant bets on the biotech firm's experimental treatments for obesity and cardiometabolic diseases, the companies said Monday. 
- 
									September 22, 2025
									ProPhase COVID-19 Testing Units Hit Ch. 11 In NJBiotechnology company ProPhase Labs Inc. put three of its COVID-19 laboratory testing subsidiaries in Chapter 11 bankruptcy Monday in New Jersey with combined liabilities of more than $13 million, saying it has been underpaid by insurance companies. 
- 
									September 21, 2025
									Chinese Exec Who Shipped Fentanyl Ingredients Gets 25 YrsA Manhattan federal judge on Friday sentenced a Chinese national and chemical company executive to 25 years in prison for shipping large quantities of fentanyl ingredients to the U.S., citing the defendant's "egregious, callous" disregard for the deaths caused by the drugs he helped create. 
- 
									September 19, 2025
									Stewart Issues Mixed Bag Of Referrals, Denied PetitionsCoke Morgan Stewart issued some of her final decisions as acting director of the U.S. Patent and Trademark Office, discretionarily denying a host of petitions for Patent Trial and Appeal Board review, while also referring a group of Apple Inc.'s petitions to the board for scrutiny. 
Expert Analysis
- 
								Opinion High Court Must Overrule Outdated Patent Eligibility Doctrine_page-0001.jpg)  A certiorari petition should directly ask the U.S. Supreme Court to correct its 1972 patent decision in Gottschalk v. Benson, the critical point where patent eligibility law veered from the statutory text toward judicial policymaking, says Robert Greenspoon at Dunlap Bennett. 
- 
								Series Playing The Violin Makes Me A Better Lawyer  Playing violin in a string quartet reminds me that flexibility, ambition, strong listening skills, thoughtful leadership and intentional collaboration are all keys to a successful legal practice, says Julie Park at MoFo. 
- 
								
								The State Of AI Adoption In The Patent Field  The use of generative artificial intelligence in patent-related practices has lagged behind early predictions, which may be explained by a number of core concerns that organizations must address before seriously considering adoption, say attorney Michael Drapkin and leadership coach Michael Colacchio. 
- 
								
								Purdue Case Could Transform Patent Obviousness Analyses  If accepted for review by the U.S. Supreme Court, Purdue Pharma v. Accord Healthcare — concerning whether Purdue's abuse-deterrent opioid formulation patents were invalid as obvious — could significantly shift how courts weigh secondary considerations in patent obviousness analyses, say attorneys at Lathrop. 
- 
								
								Federal Regs Order May Spell Harsher FDCA Enforcement  A recent executive order aimed at reducing criminal prosecutions of those who unknowingly violate complex federal regulations may actually lead to more aggressive felony indictments under the Federal Food, Drug and Cosmetic Act, but companies and executives can mitigate risks by following several key principals, say attorneys at McGuireWoods. 
- 
								Series Law School's Missed Lessons: Practicing Self-Care  Law schools don’t teach the mental, physical and emotional health maintenance tools necessary to deal with the profession's many demands, but practicing self-care is an important key to success that can help to improve focus, manage stress and reduce burnout, says Rachel Leonard​​​​​​​ at MG+M. 
- 
								
								ABA Opinion Makes It A Bit Easier To Drop A 'Hot Potato'  The American Bar Association's recent ethics opinion clarifies when attorneys may terminate clients without good cause, though courts may still disqualify a lawyer who drops a client like a hot potato, so sending a closeout letter is always a best practice, say attorneys at Thompson Hine. 
- 
								
								IRhythm IPR Denial Raises Key PTAB Discretion Questions  By giving the passage of time a dispositive role in denying institution of five inter partes review petitions filed by iRhythm Technologies, the U.S. Patent and Trademark Office has upended the strategic considerations for filing and defending against IPRs, disclosing prior art during prosecution, and engaging in licensing negotiations, say attorneys at Dentons. 
- 
								
								Canadian Suit Offers Disclosure Lesson For US Cannabis Cos.  A Canadian class action asserting that Aurora Cannabis failed to warn consumers about the risk of developing cannabinoid hyperemesis syndrome may spawn copycat filings in the U.S., and is a cautionary tale for cannabis and hemp industries to prioritize risk disclosure, says Ian Stewart at Wilson Elser. 
- 
								Opinion IPR Denial In IRhythm Should Not Set A Blanket Rule  Though the Patent Trial and Appeal Board's discretionary denial in iRhythm v. Welch Allyn last month raised concerns that mere knowledge of a patent could bar inter partes review institution, a closer look at the facts and reasoning reveals why this case's holdings should not be reflexively applied to all petitioners, says David McCombs at Haynes Boone. 
- 
								
								What High Court's Tenn. Trans Care Ruling Means Nationally  The U.S. Supreme Court's decision in U.S. v. Skrmetti, upholding a Tennessee ban on gender-affirming medical care for minors, is fairly limited in scope and closely tailored to the specific language of Tennessee's law, but it may have implications for challenges to similar laws in other states, say attorneys at Hall Render. 
- 
								
								How Trump's Trade Policies Are Shaping Foreign Investment.jpg)  Five months into the Trump administration, investors are beginning to see the concrete effects of the president’s America First Investment Policy as it presents new opportunities for clearing transactions more quickly, while sustaining risk aversion related to Chinese trade and potentially creating different political risks, say attorneys at Covington. 
- 
								Series My Opera And Baseball Careers Make Me A Better Lawyer  Though participating in opera and the world of professional baseball often pulls me away from the office, my avocations improve my legal career by helping me perform under scrutiny, prioritize team success, and maintain joy and perspective at work, says Adam Unger at Herrick Feinstein. 
- 
								Opinion Subject Matter Eligibility Test Should Return To Preemption  Subject matter eligibility has posed challenges for patentees due to courts' arbitrary and confusing reasoning, but adopting a two-part preemption test could align the applicant, the U.S. Patent and Trademark Office and the courts, says Manav Das at McDonnell Boehnen. 
- 
								
								8 Ways Lawyers Can Protect The Rule Of Law In Their Work  Whether they are concerned with judicial independence, regulatory predictability or client confidence, lawyers can take specific meaningful actions on their own when traditional structures are too slow or too compromised to respond, says Angeli Patel at the Berkeley Center of Law and Business. 
